SCHEMBL1760744

SCHEMBL1760744

CC(C)(C)OC(=O)n1ccc2c(C=O)cccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ACHE P22303 1/20 0.41
NOTUM Q6P988 1/20 0.39
BRD4 O60885 1/20 0.39
CREBBP Q92793 1/20 0.39
AKT1 P31749 1/20 0.38
BUB1 O43683 1/20 0.38
BCHE P06276 1/20 0.38
HTR6 P50406 1/20 0.36
PIM1 P11309 1/20 0.36
MARK3 P27448 1/20 0.36
MAP4K2 Q12851 1/20 0.36
CAMK2B Q13554 1/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19809548 0.88 MEN1 (0.42) MEN1KMT2AL3MBTL1ACHENOTUM
SCHEMBL26300944 0.85 L3MBTL1 (0.43) MEN1KMT2AL3MBTL1ACHENOTUM
SCHEMBL26300943 0.85 ACHE (0.41) MEN1KMT2AL3MBTL1ACHENOTUM
SCHEMBL3165880 0.83 L3MBTL1 (0.41) MEN1KMT2AL3MBTL1ACHENOTUM
SCHEMBL3165886 0.83 L3MBTL1 (0.41) MEN1KMT2AL3MBTL1ACHENOTUM
SCHEMBL3175956 0.82 ACHE (0.41) MEN1KMT2AL3MBTL1ACHENOTUM
SCHEMBL3175970 0.82 ACHE (0.41) MEN1KMT2AL3MBTL1ACHENOTUM
SCHEMBL29443981 0.82 KMT2A (0.56) MEN1KMT2AL3MBTL1ACHEBRD4
SCHEMBL3533644 0.82 KMT2A (0.56) MEN1KMT2AL3MBTL1ACHEBRD4
SCHEMBL3836430 0.81 L3MBTL1 (0.45) MEN1KMT2AL3MBTL1ACHENOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118255777-A Synthesis and application of CDK7 inhibitors 晶锐医药(苏州)有限公司 2024-06-28 CN disclosed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 US disclosed
EP-4276087-A1 BETA-ELEMENE VINYLATION COUPLED DERIVATIVE, AND PREPARATION THEREOF AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG Hangzhou Normal University (CN) 2023-11-15 EP disclosed
WO-2023160035-A1 β-ELEMENE VINYLATION COUPLED DERIVATIVE, AND PREPARATION THEREOF AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG 杭州师范大学 2023-08-31 WO disclosed
US-20220106321-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-04-07 US disclosed
US-11279704-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-03-22 US disclosed
CN-108440370-B Inhibitors of viral replication 鲁汶天主教大学 2021-07-30 CN disclosed
EP-3617192-A1 VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2020-03-04 EP disclosed
US-10550123-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-02-04 US disclosed
US-20190337954-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2019-11-07 US disclosed
WO-2016100391-A1 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS Prosetta Antiviral, Inc. (US) 2016-06-23 WO disclosed
US-20160168100-A1 ANTI-HIV COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-16 US disclosed
US-20140213586-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2014-07-31 US disclosed
US-8273745-B2 Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents ASTELLAS PHARMA INC (JP) 2012-09-25 US disclosed
EP-2094662-B1 POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS ASTELLAS PHARMA INC (JP) 2012-04-11 EP disclosed
US-7947728-B1 Indole and indazole analogs as glycogen synthase activators HOFFMANN-LA ROCHE INC. (US) 2011-05-24 US disclosed
US-20110112161-A1 INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS BOLIN DAVID ROBERT 2011-05-12 US disclosed
US-20100009991-A1 POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS ASTELLAS PHARMA INC. (JP) 2010-01-14 US disclosed
EP-2094662-A1 POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS Astellas Pharma Inc. (JP) 2009-09-02 EP disclosed
WO-2008072784-A1 POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS ASTELLAS PHARMA INC. (JP) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112161-A1 INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS GYS2, PYGL, GSK3B MEN1 3458/4885KMT2A 3311/4885L3MBTL1 4504/4885
US-20100009991-A1 POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS HRH2, HRH1, HRH4 MEN1 3534/4885KMT2A 2733/4885L3MBTL1 4881/4885
US-20140213586-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 MEN1 3390/4885KMT2A 2425/4885L3MBTL1 2136/4885
US-20160168100-A1 ANTI-HIV COMPOUNDS MAVS, SARS1, NFATC1 MEN1 2432/4885KMT2A 1269/4885L3MBTL1 579/4885
US-11279704-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 MEN1 3390/4885KMT2A 2425/4885L3MBTL1 2136/4885
US-20190337954-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 MEN1 3390/4885KMT2A 2425/4885L3MBTL1 2136/4885
US-10550123-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 MEN1 3390/4885KMT2A 2425/4885L3MBTL1 2136/4885
US-20220106321-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 MEN1 3390/4885KMT2A 2425/4885L3MBTL1 2136/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 MEN1 3390/4885KMT2A 2425/4885L3MBTL1 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.